{"id":"NCT03616899","sponsor":"Kala Pharmaceuticals, Inc.","briefTitle":"Safety and Efficacy of KPI-121 in Subjects With DED","officialTitle":"A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-10","primaryCompletion":"2020-02-05","completion":"2020-02-05","firstPosted":"2018-08-06","resultsPosted":"2021-04-02","lastUpdate":"2021-04-02"},"enrollment":901,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Kerato Conjunctivitis Sicca"],"interventions":[{"type":"DRUG","name":"KPI-121 Ophthalmic Suspension","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"KPI-121 0.25% Ophthalmic Suspension","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).","primaryOutcome":{"measure":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)","timeFrame":"Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)","effectByArm":[{"arm":"KPI-121 0.25% Ophthalmic Suspension","deltaMin":-13.58,"sd":19.379},{"arm":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","deltaMin":-8.91,"sd":17.579}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":81,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":449},"commonTop":["Instillation site pain","Dry eye","Eye pruritus","Eye irritation","Headache"]}}